Home › Compare › EVGRF vs ABBV
EVGRF yields 181818.18% · ABBV yields 3.12%● Live data
📍 EVGRF pulled ahead of the other in Year 1
Combined, EVGRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EVGRF + ABBV for your $10,000?
China Evergrande New Energy Vehicle Group Limited, an investment holding company, operates as a health management company in the People's Republic of China, Europe, and internationally. The company operates through two segments, Health Management and New Energy Vehicle. It develops and sells health and living properties; and provides community health management, medical cosmetology, and anti-aging services, as well as elderly care and rehabilitation. The company is involved in the wholesale of home care and healthcare products, as well as provision of healthcare services and software services. In addition, it engages in the research and development of pharmaceuticals; production of medical equipment; and manufacture and sale of smart mobility and lithium-ion battery. Further, the company is involved in the research, development, production, and sales of new energy vehicles and vehicle living project. The company was formerly known as Evergrande Health Industry Group Limited and changed its name to China Evergrande New Energy Vehicle Group Limited in August 2020. China Evergrande New Energy Vehicle Group Limited was founded in 1999 and is headquartered in Guangzhou, China. China Evergrande New Energy Vehicle Group Limited is a subsidiary of China Evergrande Group.
Full EVGRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.